跳至主要内容
临床试验/NCT05494450
NCT05494450终止不适用

An Open, Non-comparative, Multicenter Investigation to Evaluate the Safety and Performance of Exufiber Ag+, a Gelling Fiber Silver Dressing, When Used in Medium to High Exuding Chronic Wounds

Molnlycke Health Care AB4 个研究点 分布在 1 个国家目标入组 46 人开始时间: 2022年1月1日最近更新:
适应症

试验速览

阶段
不适用
状态
终止
发起方
入组人数
46
试验地点
4
主要终点
evaluate the safety and performance of Exufiber Ag+ in medium to high exuding chronic wounds

研究概览

简要总结

An open, non-comparative, multicenter investigation to evaluate the safety and performance of Exufiber Ag+, a gelling fiber silver dressing, when used in medium to high exuding chronic wounds

详细描述

The overall objective of this post market clinical follow-up (PMCF) investigation is to confirm performance and safety of the Exufiber Ag+ dressing in medium to high exuding chronic wounds, with Mepilex Border Flex as the secondary dressing, when used in accordance with the Instructions for Use.

研究设计

研究类型
Interventional
分配方式
Na
干预模型
Single Group
主要目的
Treatment
盲法
None

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Signed Informed Consent Form
  • Patient aged ≥18 years old
  • Patient with moderate to high exuding chronic wound (PU (stage II-IV), VLU or DFU)
  • Patient with target wound that is a shallow to deep wound or cavity
  • Patient with target wound that is ≥ 4 weeks in age
  • Patient with target wound that is ≥ 8 cm2

排除标准

  • Patient is contraindicated for the dressing according to product labeling
  • Known allergy/hypersensitivity to any of the components of the investigation products
  • Pregnancy/lactating female
  • Patient with spreading soft tissue infection/cellulitis in the wound (as judged by the Investigator)
  • Patient with known immunodeficiency
  • Patient taking systemic antibiotics
  • Patient with the target wound located on an infected limb and/or interfered by minimal blood flow in the opinion of the Investigator.
  • Patient with the target wound with an unexplored enteric fistula
  • Patient requiring treatment with oxidizing agents such as hypochlorite solutions or hydrogen peroxide
  • Patient who, in the opinion of the Investigator, is not expected to comply with the investigation due to physical and/or mental conditions
  • Patient who was previously enrolled in this investigation
  • Patient participating in other investigations that would preclude the subject from participating in this investigation as judged by the Investigator
  • Patient involved in the planning and conduct of the clinical investigation (applies to all Mölnlycke staff, investigational site staff, and third party vendor)

结局指标

主要结局

evaluate the safety and performance of Exufiber Ag+ in medium to high exuding chronic wounds

时间窗: 28 Days

open, non-comparative, multicenter investigation

次要结局

未报告次要终点

研究者

发起方
Molnlycke Health Care AB
申办方类型
Industry
责任方
Sponsor

研究点 (4)

Loading locations...

相似试验